Cancer Advance
Date: Location: Cost:
April 11, 2017 Harvard Medical School - Joseph B. Martin Conference Center
77 Avenue Louis Pasteur
Boston, MA 02115

Starting at $1950

 

Dress Code:
Business Attire

Register

Conference Details

Join some of the most distinguished cancer experts from academia and industry, alongside the people who help turn discoveries into therapies—biotech entrepreneurs, venture capitalists, buysiders, bankers and analysts—for a high-energy, uniquely interactive meeting at Harvard Medical School where networking and discussion take center stage. 

Co-hosts and speakers include: Jörn AldagCEO, Hookipa Biotech AG; Barry Brooks, Chairman, US Oncology; Paul BiondiSVP, Head, BD, Bristol-Myers Squibb; Pablo Cagnoni, President & CEO, Tizona Therapeutics; Chip Clark, President & CEO, Genocea Biosciences; George DemetriSVP, Experimental Therapeutics, Dana Farber Cancer Institute; John DeYoung, VP, Worldwide BD, Pfizer; Giulio Draetta, ‎Director, Institute for Applied Cancer Science, MD Anderson Cancer Center; Robert ForresterPresident & CEO, Verastem; Chris Guiffre, President & CEO, Cerulean Pharma; JC Gutierrez-Ramos, CEO, Synlogic Therapeutics; Jim Healy, Managing General Partner, Sofinnova Ventures; John HerrmannExpert Partner & SVP, Oncology, Catenion; Rachel HumphryCMO, CytomX; Arthur KriegFounder & CEO, Checkmate Pharmaceuticals; Jonathan Lewis, CEO, Samus Therapeutics; Niven NarainCo-Founder, President, & CEO, Berg; Bob OliverPresident & CEO, Otsuka; Ferran Prat, VP, Strategic Industry Ventures, MD Anderson Cancer Center; Robert Radinsky, VP, Oncology Scientific Innovation, Janssen R&D, Oliver RosenCMO, Deciphera; Bob SilvermanHead, Externalized Drug Discovery Partnering, Roche; Kristine SwiderekCSO, OncoResponse; Daniel TeperCEO, Immune Pharmaceuticals; Pascal TouchonSVP Global Head, Strategy & BD, Novartis Oncology; Beth TrehuCMO, Jounce Therapeutics; Guillaume VignonHead, IO Licensing & BD, Merck KGaA; Arthur WrightChief Medical Officer, Roche Diagnostics

Testimonials:
“Cancer Advance is one of the must-attend cancer conferences for colleagues in the cancer field. Boston and the eco-system are at the leading edge of cutting edge breakthroughs. Learning and interacting with the thought leaders is why I attend.” -- David Meek, CEO, IPSEN

Hear the Latest at Cancer Advance Boston:

  • Learn what biotechs are doing to revolutionize clinical trial design
  • Hear the latest in Immunotherapy and Combination Therapy
  • Understand the application of liquid biopsies and cutting edge science
  • Hear details on some of the most innovative deals and partnerships in oncology
  • Understand enhanced commercialization strategies
  • Get insight from industry leaders on the hottest trends to watch and predictions for the future

Premier Sponsors: (see all sponsors)